NBIX – neurocrine biosciences, inc. (US:NASDAQ)
Stock Stats
News
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target lowered by analysts at UBS Group AG from $154.00 to $137.00. They now have a "buy" rating on the stock.
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer [Yahoo! Finance]
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia [Yahoo! Finance]
Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia
Form 8-K NEUROCRINE BIOSCIENCES For: Apr 02
Form SCHEDULE 13G/A NEUROCRINE BIOSCIENCES Filed by: VANGUARD GROUP INC
Form 4 NEUROCRINE BIOSCIENCES For: Feb 12 Filed by: Cooke Julie
Form 4 NEUROCRINE BIOSCIENCES For: Feb 13 Filed by: GORMAN KEVIN CHARLES
Form 4 NEUROCRINE BIOSCIENCES For: Feb 13 Filed by: SHERWIN STEPHEN A
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.